Sat, Jan 31, 2015, 5:06 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Federal National Mortgage Association Message Board

itchibahn 3 posts  |  Last Activity: Jan 29, 2015 10:54 AM Member since: Jan 5, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    what should i do?

    by bas111in Jan 29, 2015 10:35 AM
    itchibahn itchibahn Jan 29, 2015 10:54 AM Flag

    Perhaps, buy some more to lower your average, then sell some (not all) on small pops. Repeat the process. It lowers you overall losses drastically, some cases breakeven or even small profit. It worked for me on couple tickers.

    If you have no more cash to work with, then hold until it makes small pop. Then sell half, wait for it to consolidate and buy back. Repeat the process.

    Other option would be to dump it, move onto next ticker and don't look back.

    None is attractive, but you gotta pick your poison. GL.

  • itchibahn itchibahn Jan 29, 2015 10:19 AM Flag

    Not "dead" yet.

    "...continuing to seek U.S. regulatory approval for APPY1, exploring study protocols to address matters identified by the FDA, assessing the acceleration of our APPY2 next generation product and pursuing our commercial advances being made in Europe."

    "We believe that the strong clinical trial results we achieved and the additional clinical utility information we provided to the FDA in responses to its requests for additional information were compelling, and we intend to continue to work with the FDA to advance the progress of a blood-based diagnostic test to assist in the evaluation of appendicitis."

  • Read up at Zogenix website. Remember that agreement between Zogenix and Purdue?

    SAN DIEGO, Oct. 31, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has entered into an agreement with Purdue Pharma L.P. (Purdue) under which the two companies have exchanged waivers of regulatory exclusivity applicable to their respective single-entity, extended-release hydrocodone products. These waivers are applicable to current or pending New Drug Applications (NDAs) as well as successor products, including those with abuse-deterrent properties and associated labeling claims.

    In connection with the exchange of waivers, Purdue has agreed to pay Zogenix $10 million with the first payment of $5 million due within 15 days and the second-half payment due on July 1, 2015. Zogenix may also be eligible to receive royalties on future net sales of Purdue's once-daily hydrocodone product, for a limited period of time, if certain sales conditions are met.

FNMA.OB
2.10-0.12(-5.41%)Oct 30 2:37 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Amazon.com Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST
Eldorado Gold Corporation
NYSEFri, Jan 30, 2015 4:02 PM EST